EunetHTA has developed several tools to support the conduciton of Joint Assessments, but also to facilitate the collection of evidence from the companies.
A joint assessment is a structured information for rapid or full/comprehensive HTAs which is the output of joint production in which 2 or more countries and/or organisations work together to prepare shared products or agreed outcomes (Based on definitions from the HTA Network Strategy (page 24) and the EUnetHTA Recommendations (page 6, footnote 8))
Methodological guideline for REA of pharmaceuticals: Health-related quality of life
JA-WP5 EUnetHTA Joint Action (2010-12)
2013 - PDF
This guideline provides a set of recommendations for the selection and assessment of Health-related quality of life (HRQoL) when completing a Relative Effectiveness Assessment (REA) of pharmaceuticals.
Health-related quality of life (HRQoL) is often considered to be an important endpoint of health care interventions. Because improvement in HRQoL is highly subjective, it does not necessarily correlate well with objectively measurable clinical benefits.
This guidance indicates which types of HRQoL measures are suitable for the demonstration of the relative effectiveness of pharmaceuticals and summarizes the caveats for interpreting HRQoL outcomes. It has a double purpose: (1) support assessors in identifying the strengths and weaknesses in the evidence provided and (2) inform researchers about the requirements regarding HRQoL assessment in order to allow them to anticipate the collection of the required data for REA when developing trial protocols.
Please find the guideline on health-related quality of life at the bottom of this page
This document is part of the JA1 Final Technical Report as Deliverable "D3-2 WP5_3a5_HRQoL" NOTE: For the full Technical Report, please follow this link.
